Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients

Summary

The main objective of this study is to identify epigenetic markers specific to abnormal myeloid cells in patients with acute myeloid leukemia (AML) by analyzing the methylation of circulating cell-free DNA in plasma.

Eligibility

1. / Control Group

   Inclusion Criteria:
   * Age ≥ 60 years;
   * Scheduled for cardiac surgery involving sternotomy;
   * Normal blood count within the two months preceding sampling;
   * Affiliated with, or beneficiary of, a social security system;
   * Written informed consent to participate in the study.

   Exclusion Criteria:
   * Patients deemed unsuitable for sampling by the surgeon performing the procedure;
   * Patients under legal protection measures;
   * Patients under judicial supervision or deprived of liberty by judicial or administrative decision;
   * Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV).
2. / AML Group

Inclusion Criteria:

* Age ≥ 60 years;
* Diagnosis of de novo AML or AML secondary to myelodysplastic syndrome, scheduled to receive azacitidine-based treatment;
* Affiliated with, or beneficiary of, a social security system;
* Written informed consent to participate in the study.

Exclusion Criteria:

* Diagnosis of a hematologic disease other than AML;
* Clinical signs suggestive of active central nervous system leukemia, or presence of isolated extramedullary leukemia;
* Previous treatment for AML other than hydroxyurea;
* Severe comorbidities that could interfere with the study, as assessed by the principal investigator;
* Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV);
* Patients under legal protection;
* Patients under judicial supervision or deprived of liberty by judicial or administrative decision.

Conditions2

Browse More Trials